EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 842 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Coming Full Circle on Cancer and Extrachromosomal DNA May 10, 2023 Dame Deborah James: why do deeply personal stories resonate with us... May 24, 2022 Patient Exposure to Anticancer Drugs Subsequently Withdrawn from the FDA Accelerated... March 9, 2023 COVID-19, Cancer, and Uncertainty: An Oncologist’s Perspective on Coping November 17, 2020 Load more HOT NEWS First Direct Comparison of Ibrutinib versus Acalabrutinib in Patients with Previously... FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax... EMA Recommends Extension of Indications for Tafasitamab Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in...
